← Back to Patent Explorer
US5284655A Expired / Lapsed US ⏱️ 0.0 years remaining

Swollen demineralized bone particles, flowable osteogenic composition containing same and use of the composition in the repair of osseous defects

Assignee: Warsaw Orthopedic Inc
•
Filing: 1992-02-04
•
Granted: 1994-02-08
•
Expires: 2012-02-04
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Swollen demineralized bone particles are formulated into a flowable osteogenic composition which is useful in the repair of osseous defects.

Inventors

  • 👤 Simon Bogdansky
  • 👤 Robert K. O'Leary

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 02:07
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/3604; A61L27/3608; A61B; A61B17/00; A61B17/56; A61B17/58; A61B17/68; A61B17/686; A61B17/82; A61F; A61F2/00; A61F2/02; A61F2/28; A61F2/2803; A61F2/2846; A61F2/30; A61F2/46; A61F2/4644; A61K; A61K35/00; A61K35/12; A61K35/32; A61L24/00; A61L24/0005; A61L27/14; A61L27/22; A61L27/227; A61L27/3641; A61L27/3645; A61L27/365; A61L27/3683; A61F2/44; A61F2/4455; A61F2002/2817; A61F2002/2835; A61F2002/30001; A61F2002/30003; A61F2002/3006; A61F2002/30075; A61F2002/30108; A61F2002/30199; A61F2002/302; A61F2002/30224; A61F2002/30235; A61F2002/30261; A61F2210/00; A61F2210/0061; A61F2230/00; A61F2230/0063; A61F2230/0065; A61F2230/0069; A61F2230/0082; A61L2400/00; A61L2400/06; A61L2430/00; A61L2430/02

Claims Analysis

Total Claims: 21
Claim 1
Independent Claim 135 words
A flowable osteogenic composition which comprises from about 5 to about 90 weight percent swollen demineralized autogenous or allogenic bone particles exhibiting an average increase in volume and/or weight of at least about 10 percent following contact of the unswollen demineralized bone particles with a demineralized bone particle swelling agent and from about 10 to about 95 weight percent of a biocompatible fluid carrier selected from a member of the group consisting of liquid polyhydroxy compound, liquid ester of a polyhydroxy compound, liquid solution of a solid polyhydroxy compound, liquid solution of a solid ester of a polyhydroxy compound and mixtures thereof, wherein the polyhydroxy compound is selected from the group consisting of acyclic polyhydric alcohols, polyalkylene glycols, non-reducing sugars, sugar alcohols, sugar acids, monosaccharides, disaccharides, water-soluble or water dispersible oligosaccharides, polysaccharides and mixtures thereof.
Claim 2
Dependent Claim 135 words
A flowable osteogenic composition which comprises from about 5 to about 90 weight percent swollen demineralized autogenous or allogenic bone particles exhibiting an average increase in volume and/or weight of at least about 10 percent following contact of the unswollen demineralized bone particles with a demineralized bone particle swelling agent and from about 10 to about 95 weight percent of a biocompatible fluid carrier selected from a member of the group consisting of liquid polyhydroxy compound, liquid ester of a polyhydroxy compound, liquid solution of a solid polyhydroxy compound, liquid solution of a solid ester of a polyhydroxy compound and mixtures thereof, wherein the polyhydroxy compound is selected from the group consisting of acyclic polyhydric alcohols, polyalkylene glycols, non-reducing sugars, sugar alcohols, sugar acids, monosaccharides, disaccharides, water-soluble or water dispersible oligosaccharides, polysaccharides and mixtures thereof.
Claim 3
Dependent Claim 75 words
The composition of claim 1 containing at least one additional component selected from the group consisting of antiviral agent, antimicrobial agent, antibiotic agent, amino acid, peptide, vitamin, protein synthesis co-factor, hormone, endocrine tissue, synthesizer, enzyme, polymer-cell scaffolding agent with parenchymal cells, angiogenic drug, collagen lattice, antigenic agent, cytoskeletal agent, mesenchymal stem cells, bone digester, antitumor agent, cellular attractant, fibronectin, growth hormone cellular attachment agent, immunosuppressant, nucleic acid, surface active agent, hydroxy apatite and penetraction enhancer.
Claim 4
Dependent Claim 37 words
The swollen demineralized bone particles of claim 1 exhibiting an average increase in volume and/or weight of at least about 20 percent following contact of the unswollen demineralized bone particles with the demineralized bone particle swelling agent.
Claim 5
Dependent Claim 37 words
The swollen demineralized bone particles of claim 1 exhibiting an average increase in volume and/or weight of at least about 30 percent following contact of the unswollen demineralized bone particles with the demineralized bone particle swelling agent.
Claim 6
Dependent Claim 24 words
The composition of claim 1 wherein the swollen demineralized bone particles have an average maximum dimension of from about 0.01 to about 10 mm.
Claim 7
Dependent Claim 32 words
The composition of claim 1 wherein the carrier is glyceryl monolaurate dissolved in a solvent selected from the group consisting of propylene glycol, glycerol, monoacetin, diacetin, liquid polyethylene glycol and mixtures thereof.
Claim 8
Dependent Claim 28 words
The composition of claim 1 containing from about 20 to about 80 weight percent swollen demineralized bone particles and from about 20 to about 80 weight percent carrier.
Claim 9
Dependent Claim 21 words
The composition of claim 1 wherein the carrier is selected from the group consisting of glycerol, glycerol monoester and glycerol diester.
Claim 10
Dependent Claim 27 words
The composition of claim 1 wherein the carrier is selected from the group consisting of monosaccharide, monosaccharide ester, disaccharide, disaccharide ester, oligosaccharide, oligosaccharide ester and mixtures thereof.
Claim 11
Dependent Claim 10 words
The composition of claim 10 wherein the carrier is dextran.
Claim 12
Dependent Claim 173 words
A flowable osteogenic composition which comprises from about 5 to about 90 weight percent swollen demineralized autogenous or allogenic bone particles exhibiting an average increase in volume and/or weight of at least about 10 percent following contact of the unswollen demineralized bone particles with a demineralized bone particle swelling agent and from about 10 to about 95 weight percent of a biocompatible fluid carrier selected from a member of the group consisting of liquid polyhydroxy compound, liquid ester of a polyhydroxy compound, liquid solution of a solid polyhydroxy compound, liquid solution of a solid ester of a polyhydroxy compound and mixtures thereof, wherein the polyhydroxy compound is selected from the group consisting of ethylene glycol, diethylene glycol, triethylene glycol, 1,2-propanediol, glycerol, trimethylolethane, trimethylopropane, erythritol, pentaerythritol, polyethylene glycols, polyvinylalcohols, xylitol, sorbitol, mannitol, dulcitol, arabinose, xylose, ribose, adonitol, arabitol, rhamose, inositol, fructose, galactose, glucose, mannose, sorbose, sucrose, dextrose, maltose, lactose, maltitol, lactitol, stachyose, maltopentaose, eyclomaltohexaose, carrageenan, agar, dextran, alginic acid, guar gum, gum tragacanth, locust bean gum, gum arabic, xanthan gum, amylose and mixtures thereof.
Claim 13
Dependent Claim 173 words
A flowable osteogenic composition which comprises from about 5 to about 90 weight percent swollen demineralized autogenous or allogenic bone particles exhibiting an average increase in volume and/or weight of at least about 10 percent following contact of the unswollen demineralized bone particles with a demineralized bone particle swelling agent and from about 10 to about 95 weight percent of a biocompatible fluid carrier selected from a member of the group consisting of liquid polyhydroxy compound, liquid ester of a polyhydroxy compound, liquid solution of a solid polyhydroxy compound, liquid solution of a solid ester of a polyhydroxy compound and mixtures thereof, wherein the polyhydroxy compound is selected from the group consisting of ethylene glycol, diethylene glycol, triethylene glycol, 1,2-propanediol, glycerol, trimethylolethane, trimethylopropane, erythritol, pentaerythritol, polyethylene glycols, polyvinylalcohols, xylitol, sorbitol, mannitol, dulcitol, arabinose, xylose, ribose, adonitol, arabitol, rhamose, inositol, fructose, galactose, glucose, mannose, sorbose, sucrose, dextrose, maltose, lactose, maltitol, lactitol, stachyose, maltopentaose, eyclomaltohexaose, carrageenan, agar, dextran, alginic acid, guar gum, gum tragacanth, locust bean gum, gum arabic, xanthan gum, amylose and mixtures thereof.
Claim 14
Dependent Claim 14 words
The composition of claim 1 wherein the carrier is a liquid solution of sucrose.
Claim 15
Dependent Claim 14 words
The composition of claim 1 wherein the carrier is an aqueous solution of sucrose.
Claim 16
Dependent Claim 19 words
The composition of claim 1 wherein the carrier is a liquid solution of a fatty acid monoester of glycerol.
Claim 17
Dependent Claim 27 words
The composition of claim 1 wherein the carrier is a fatty acid monoester dissolved in a solvent which is a different liquid polyhydroxy compound and/or ester thereof.
Claim 18
Dependent Claim 131 words
A flowable osteogenic composition which comprises from about 5 to about 90 weight percent swollen demineralized autogenous or allogenic bone particles exhibiting an average increase in volume and/or weight of at least about 10 percent following contact of the unswollen demineralized bone particles with a demineralized bone particle swelling agent and from about 10 to about 95 weight percent of a biocompatible fluid carrier selected from a member of the group consisting of liquid polyhydroxy compound, liquid ester of a polyhydroxy compound, liquid solution of a solid polyhydroxy compound, liquid solution of a solid ester of a polyhydroxy compound and mixtures thereof, wherein the carrier is a fatty acid monoester dissolved in a solvent selected from the group consisting of propylene glycol, glycerol, monoacetin, diacetin, liquid polyethylene glycol and mixtures thereof.
Claim 19
Dependent Claim 131 words
A flowable osteogenic composition which comprises from about 5 to about 90 weight percent swollen demineralized autogenous or allogenic bone particles exhibiting an average increase in volume and/or weight of at least about 10 percent following contact of the unswollen demineralized bone particles with a demineralized bone particle swelling agent and from about 10 to about 95 weight percent of a biocompatible fluid carrier selected from a member of the group consisting of liquid polyhydroxy compound, liquid ester of a polyhydroxy compound, liquid solution of a solid polyhydroxy compound, liquid solution of a solid ester of a polyhydroxy compound and mixtures thereof, wherein the carrier is a fatty acid monoester dissolved in a solvent selected from the group consisting of propylene glycol, glycerol, monoacetin, diacetin, liquid polyethylene glycol and mixtures thereof.
Claim 20
Dependent Claim 15 words
The composition of claim 1 wherein the carrier is glycerol monolaurate dissolved in a solvent.
Claim 21
Dependent Claim 25 words
The composition of claim 1 wherein the carrier is glycerol monolaurate dissolved in a solvent which is a different liquid polyhydroxy compound and/or ester thereof.

References Cited (Backward Citations)

US3458397A Cited
US4191747A Cited
SU880425A1 Cited
US4440750A Cited
US4458733A Cited
US4563489A Cited
US4595713A Cited
US5053049A Cited
US5162114A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1997-02-07 1997-08-09 1998-02-08 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2001-02-07 2001-08-09 2002-02-08 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2005-02-07 2005-08-09 2006-02-08 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag